CXCL8 and cancer: HuMax-IL8 (BMS-986253), an inhibitor of CXCL8, has been demonstrated to be well-tolerated in patients with advanced cancers and is currently being evaluated for its safety and efficacy in combination with nivolumab (NCT03400332) (50, 114).